Development of a novel therapeutic for AIDS rapidly disseminating in Okinawa and evaluation of it using humanized mouse model

作为控制艾滋病/人类免疫缺陷病毒1型（HIV-1）感染的新药候选物，评价了表达HIV-1受体和CXCR 4拮抗剂的重组水泡性口炎病毒（VSV）。在体外实验和移植人外周血单个核细胞或人造血干细胞的免疫缺陷小鼠（人源化小鼠）实验中，两种候选物均能明确抑制HIV-1感染，表明它们对AIDS/HIV-1感染具有潜在的治疗价值。

As candidates for novel drugs to control AIDS/human immunodeficiency virus type 1 (HIV-1) infection, a recombinant vesicular stomatitis virus (VSV) expressing HIV-1 receptors and CXCR4 antagonist were evaluated. In vitro and in immunodeficient mice transplanted with human peripheral blood mononuclear cells or with human hematopoietic stem cells (humanized mice), both candidates could inhibit HIV-1 infection definitely, indicating that they have a potentially therapeutic value for AIDS/HIV-1 infection.